



BJCN

BULGARIAN JOINT
CANCER NETWORK

Bulgarian Joint Cancer Network

UIC 206887995

15, Acad. Andrey Saharov Str., Bld. 1, Ent. A, Fl. 3, Studio 19
9009 Varna, Bulgaria

Tel.: +359 52 093 283; +359 888 537 871

E-mail: board@bjcn.bg

Web: www.bjcn.bg

Bulgarian Joint Cancer Network (BJCN) Annual Assembly 2025

BJCN-MORÉ 2025 National Oncology Conference

Management of Cervical Cancer

Prevention and the Patient Pathway with Quality Indicators

The GRADE Approach – Contextualization and Adaptation in National Guidelines

9 – 12 October 2025

SCIENTIFIC PROGRAMME

Thursday, 9 October 2025

15:00 – 15:15 Official Opening Ceremony

15:15 – 17:40 FIRST PLENARY SESSION

Diagnostic and Pretreatment Challenges in Cervical Cancer

Chair: *Assoc. Prof. Dr. I. Karagyzov*

15:15 – Molecular Pathogenetic Mechanisms of HPV-Induced Cervical Carcinoma
Dr. L. Balabanski, Acad. Prof. Dr. D. Toncheva

15:35 – 15:50 From Precursor Lesions to Invasive Carcinoma
Assoc. Prof. Dr. V. Ivanova

15:55 – 16:10 Pathological Staging with FIGO 2018 and AJCC 2021 – Parallels and Reclassifications
Assoc. Prof. Dr. I. Ivanov

16:15 – 16:30 Bulgaria – Between HPV Vaccination and Screening Programme
Assoc. Prof. Dr. I. Karagyzov

16:35 – 16:50 Cervical Cytopathology – Partly Old, Partly New
Assoc. Prof. Dr. S. Bachurska

16:55 – 17:10 MRI Versus CT for Initial Staging – Advantages and Equivalencies
Assoc. Prof. Dr. M. Penkov, Assoc. Prof. P. Getsov, Dr. S. Nedyalkova, Assoc. Prof. Dr. V. Stoyanova

17:15 – 17:35 Squamous Cell Carcinoma Antigen (SCC Ag) – Prognostic and Predictive Role
Dr. V. Koleva

**17:40 – 18:20 Industry-Supported Symposium – Varia-1**

Chair: *Dr. K. Koynov*

17:40 – 18:00 Corporate Presentation – Novartis

Two cases with one therapy: *Kisqali*. Clinical experience in postmenopausal HR+/HER2- advanced breast cancer

Dr. V. Yordanov

Dr. V. Kanarev

18:00 – 18:20 Corporate Presentation – Pfizer

Importance of the body of evidence in the treatment of HR+/HER2- metastatic breast cancer with *palbociclib*

Dr. V. Popov

19:00 Welcome Dinner**Friday, 10 October 2025****09:00 – 10:20 SECOND PLENARY SESSION****Presurgical Strategies in Cervical Cancer**

Chair: *Prof. Dr. Y. Kornovski*

09:00 – 09:15 Preoperative Sentinel Lymph Node Mapping – Hybrid Techniques and Clinical Benefit

Assoc. Prof. Dr. V. Hadzhiyska

09:20 – 09:35 Sentinel Lymph Node Biopsy – Alternative or Standard of Care?

Assoc. Prof. Dr. A. Yordanov

09:40 – 09:55 Artificial Intelligence–Assisted Colposcopy in the Diagnosis of Premalignant and Malignant Cervical Lesions

Prof. Dr. S. Kovachev

10:00 – 10:15 Cervical Cancer in the Context of Multiple Primary Cancers

Dr. M. Koleva

10:20 – 10:45 Coffee Break**10:45 – 12:35 FIRST JOINT BJCN–CCI4EU SESSION****Driving quality through measurement: embedding patient pathways**

Moderators: *Assoc. Prof. Dr. M. Penkov, M.Pharm. I. Petrov*

10:45 – 10:55 Restoring Primary Prevention and Reducing Inequalities in Europe
Restoring Primary Prevention and Reducing Inequalities in Europe

Marius Geanta

11:05 – 11:15 Cervical cancer pathway – development and implementation for quality improvement

Dr. Nadya Dimitrova

11:15 – 11:25 Quality indicators for cervical cancer care – results from the pilot data collection

Dr. Dimo Manov



11:25 – 11:35 Fertility-sparing surgery in patients with cervical and endometrial cancer – the gynecologists' repentance

Dr. Georgi Stamenov

11:35 – 11:45 Colorectal cancer patient pathway: principles, design, quality indicators, challenges, outcomes and the importance of data

Dr. Dorota Dudek-Godeau

11:45 – 11:55 Colorectal cancer patient pathway in Bulgaria: progress so far and what comes next

Dr. Dorotea Ivanova

Dr. Dimitria Valcheva

11:55 – 12:05 Comprehensive cancer center infrastructure: back to the basics

Prof. Dr. Serge Evrard

12:05 – 12:15 Comprehensive cancer center infrastructure in Bulgaria: progress so far and what comes next

Assoc. Prof. Dr. Assya Konsoulova

12:15 – 12:35 Discussion

12:35 – 13:30 Lunch

13:30 – 14:30 Industry-Supported Symposium – MSD

Modern approach to the treatment of locally advanced and metastatic cervical cancer

Moderator: *Assoc. Prof. Dr. A. Konsoulova*

The place of *pembrolizumab* in the therapy of locally advanced cervical cancer

Dr. I. Tonev

Contemporary challenges in the treatment of metastatic, recurrent and persistent cervical carcinoma

Assoc. Prof. Dr. D. Kalev

14:35 – 16:15 THIRD PLENARY SESSION

Surgical Strategies in Cervical Cancer

Chair: *Prof. Dr. P. Markov*

14:35 – 14:50 Preoperative Conization in Early-Stage Disease – A Multimodal Strategy

Prof. Dr. Y. Kornovski

14:55 – 15:10 Fertility-Sparing Surgical Strategies in Early-Stage Disease

Prof. Dr. N. Hinkova

15:15 – 15:30 Minimally Invasive Hysterectomy in Early-Stage Disease – Surgical or Oncologic Advantages?

Acad. Prof. Dr. G. Gorchev, Dr. D. Dimitrov

15:35 – 15:50 Pelvic Lymph Node Dissection in Early-Stage Disease – When Can It Be Omitted?

Prof. Dr. P. Markov

15:55 – 16:10 Surgery for Recurrent Disease

Corresponding Member Prof. Dr. S. Tomov, Dr. G. Prandzhev

16:15 – 16:45 Coffee Break

16:45 – 17:20 SECOND JOINT BJCN SESSION

Integrative Oncology

Chair: *Dr. P. Zagorchev*

16:45 – 17:00 The Role of Nutrition in Cervical Cancer

Prof. Dr. D. Naydenova

17:00 – 17:15 Integrative Approach with Homeopathic Treatment During
Radiotherapy for Malignant Neoplasms

Dr. P. Zagorchev

17:20 – 18:00 Industry-Supported Symposium – *Pierre Fabre*

**Optimal strategy in patients with metastatic colorectal cancer: from biomarkers
to therapeutic impact in real-world clinical practice**

Moderator: *Assoc. Prof. Dr. A. Konsoulova*

The role of BRAF testing in navigating therapeutic decisions

Assoc. Prof. Dr. S. Bachurska

BRAF-mutated colorectal cancer: personalized medicine in action

Dr. B. Iliev

18:05 – 18:45 Industry-Supported Symposium – *Varia-2*

Chair: *Dr. T. Zlatanova*

18:05 – 18:25 Corporate Presentation – *Roche*

*Atezolizumab as standard of care for patients with advanced stage small cell lung
cancer*

Dr. B. Iliev

18:25 – 18:45 Corporate Presentation – *Johnson & Johnson*

Johnson & Johnson medications for the treatment of advanced prostate cancer

Dr. R. Mangaldjiev

19:00 Dinner

Saturday, 11 October 2025

09:00 – 10:40 FOURTH PLENARY SESSION

Imaging and Radiotherapeutic Approaches in Cervical Cancer

Chair: *Prof. Dr. I. Mihaylova*

09:00 – 09:15 ¹⁸F-FDG PET/CT–Guided Radiotherapy and Systemic Therapy

Prof. Dr. E. Piperkova, Assoc. Prof. Dr. L. Chavdarova

09:20 – 09:35 Concurrent Chemoradiotherapy for Locally Advanced Disease with
Novel Combination Strategies (ICIs, AAAs, PARPi)

Prof. Dr. T. Hadzhieva, Dr. D. Ivanova

09:40 – 09:55 The Role of Additional Brachytherapy in the Postoperative Setting

Dr. K. Nedev



10:00 – 10:15 Intraoperative Radiotherapy in Recurrent Disease

Prof. Dr. I. Mihaylova

10:20 – 10:35 *Re-irradiation in Recurrent Disease*

Assoc. Prof. Dr. V. Popov

10:40 – 11:00 Coffee Break

11:00 – 12:20 FIFTH PLENARY SESSION

Systemic Strategies in Cervical Cancer

Chair: *Assoc. Prof. Dr. A. Konsulova*

11:00 – 11:15 Precision Systemic Strategies Based on Molecular Targets

Dr. R. Mangaljiev

11:20 – 11:35 Neoadjuvant Chemotherapy – Prior to Chemoradiotherapy or Radical Surgery

Dr. K. Koynov

11:40 – 11:55 Adjuvant Chemotherapy – Evidence and Controversies

Assoc. Prof. Dr. A. Konsulova

12:00 – 12:15 Systemic Strategies in Neuroendocrine Cervical Carcinoma

Dr. T. Zlatanova

12:20 – 12:35 Official Ceremony: Presentation of the Annual BJCN–MORE Award for Contributions to Bulgarian Clinical Oncology

12:35 – 13:35 Lunch

13:35 – 14:35 Industry-Supported Symposium – Swixx BioPharma

Future of effective treatment for urothelial carcinoma: innovation, partnerships and the road ahead with *Opdivo*

Moderator: *Assoc. Prof. Dr. D. Kalev*

From diagnosis to treatment: The role of the urologist in urothelial carcinoma

Assoc. Prof. Dr. K. Petkova

Immunotherapy in action

Dr. B. Iliev

14:40 – 15:20 Industry-Supported Symposium – Varia-3

Chair: *Dr. R. Mangaljiev*

14:40 – 15:00 **Corporate Presentation – AstraZeneca**

Diagnostics with a mission: innovative solutions from precision medicine in the treatment of breast and lung cancer

Moderator: *Assoc. Prof. Dr. S. Bachurska*

How important is precise HER2 assessment in real-world clinical practice?

Dr. F. Odjakov

20 years of EGFR: FLAURA 2 – the next step in personalized first-line therapy for metastatic non-small cell lung cancer

Dr. V. Popov

15:00 – 15:20 Corporate Presentation – Astellas

The benefits of intensification of systemic treatment in non-metastatic hormone-sensitive prostate cancer

Dr. V. Kanarev

15:25 – 17:00 THIRD JOINT BJCN SESSION

The GRADE Approach: Contextualization and Adaptation in National Oncology Guidelines

Moderator: *Prof. Dr. A. Julianov*

15:25 – 15:55 Keynote Lecture 1: The GRADE Approach – What Is New and How It Will Evolve

Prof. Holger Schünemann

15:55 – 16:25 Keynote Lecture 2: GRADE and the BJCN Guidelines

Prof. Gordon Guyatt

16:25 – 16:40 A Patient-Oriented, GRADE-Based AI Assistant for Multidisciplinary Tumor Board Decision-Making: Design and Validation

Hristo Ivanov

16:40 – 17:00 Discussion

17:00 – 17:30 Coffee Break

17:30 – 18:30 BJCN General Assembly

19:30 Dinner

Sunday, 12 October 2025

09:00 – 12:00 STRATEGIC BJCN WORKSHOP

Building a Bulgarian National Hub of the Mission Against Cancer: processes and interactions with stakeholders

Moderators: *Assoc. Prof. Dr. A. Konsoulova, M. Pharm. I. Petrov*

With the participation of representatives from all organizations, members of BJCN

12:00 – 12:10 Official Closing